APOGEE THERAPEUTICS INC. - COMMON STOCK

45,81

27-декабря-24 15:45:00

15 мин. задержка

Акции

-1,37

-2,90%

Сегодняшний диапазон

44,94 - 46,81

ISIN

N/A

Источник

NASDAQ

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

10 дек 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

02 дек 2024 05:00:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics Announces Agenda for Virtual R&D Day

29 ноя 2024 12:00:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

18 ноя 2024 06:30:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

12 ноя 2024 06:00:01 Источник Nasdaq GlobeNewswire
Apogee Therapeutics to Participate in Upcoming November Investor Conferences

04 ноя 2024 06:30:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

24 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

16 окт 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

12 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

09 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

19 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

12 авг 2024 05:30:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

28 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics to Participate in Upcoming June Investor Conferences

23 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

15 май 2024 15:01:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

13 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

06 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

25 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

12 мар 2024 15:01:00 Источник Nasdaq GlobeNewswire
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

07 мар 2024 17:49:51 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.